Faculty
Oncology Division
Alphabetical list (active faculty):   
Shunqiang Li

Shunqiang Li, PhD

Assistant Professor

Department of Medicine

Oncology Division

Molecular Oncology

Research Interests

  • Patient-derived tumor xenograft (PDX) models
  • Cancer genomics and proteomics
  • Preclinical study of anticancer drugs
  • Personalized cancer therapy

Contact

  • 314-747-9320 (lab)
  • 314-747-9320 (fax)
  • Division of Oncology
    Campus Box 8076
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Couch Biomedical Research Building, Room 3307 (office)

Original Articles

  • Transcriptional Reprogramming Differentiates Active From Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
    Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ
    Cancer Res 2021 Oct 28; [Epub ahead of print]
  • Comprehensive Characterization of 536 Patient-Derived Xenograft Models Prioritizes Candidates For Targeted Treatment
    Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, DiPersio JF, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L
    NCI PDXNet Consortium

    Nat Commun 2021 Aug 24;12(1):5086
  • Deep Learning Segmentation of Triple-Negative Breast Cancer (TNBC) Patient Derived Tumor Xenograft (PDX) and Sensitivity of Radiomic Pipeline to Tumor Probability Boundary
    Dutta K, Roy S, Whitehead TD, Luo J, Jha AK, Li S, Quirk JD, Shoghi KI
    Cancers (Basel) 2021 Jul 28;13(15)
  • Co-Clinical FDG-PET Radiomic Signature in Predicting Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Roy S, Whitehead TD, Li S, Ademuyiwa FO, Wahl RL, Dehdashti F, Shoghi KI
    Eur J Nucl Med Mol Imaging 2021 Jul 30; [Epub ahead of print]
  • Mismatch Repair Deficiency Predicts Response to HER2 Blockade in HER2-Negative Breast Cancer
    Punturi NB, Seker S, Devarakonda V, Mazumder A, Kalra R, Chen CH, Li S, Primeau T, Ellis MJ, Kavuri SM, Haricharan S
    Nat Commun 2021 May 19;12(1):2940
  • Therapeutic Targeting of Nemo-Like Kinase in Primary and Acquired Endocrine-Resistant Breast Cancer
    Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea MJ, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XS
    Clin Cancer Res 2021 May 1;27(9):2648-2662
  • Chromosome 8 Gain Is Associated With High-Grade Transformation in MPNST
    Dehner C, Moon CI, Zhang X, Zhou Z, Miller C, Xu H, Wan X, Yang K, Mashl J, Gosline SJ, Wang Y, Zhang X, Godec A, Jones PA, Dahiya S, Bhatia H, Primeau T, Li S, Pollard K, Rodriguez FJ, Ding L, Pratilas CA, Shern JF, Hirbe AC
    JCI Insight 2021 Mar 22;6(6)
  • Hormonal Modulation of ESR1 Mutant Metastasis
    Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Ando S, Fuqua SAW
    Oncogene 2021 Feb;40(5):997-1011
  • Conservation of Copy Number Profiles During Engraftment and Passaging of Patient-Derived Cancer Xenografts
    Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH
    PDXNET Consortium

    Nat Genet 2021 Jan;53(1):86-99
  • RON Signalling Promotes Therapeutic Resistance in ESR1 Mutant Breast Cancer
    Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, Welm AL, Fuqua SAW
    Br J Cancer 2021 Jan;124(1):191-206
  • Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models
    Guo Z, Primeau T, Luo J, Zhang C, Sun H, Hoog J, Gao F, Huang S, Edwards DP, Davies SR, Aft R, Ding L, Ellis MJ, Li S, Ma CX
    Cancers (Basel) 2020 Dec 21;12(12)
  • Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy
    Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, Miles G, Mertins P, Geffen Y, Tang LC, Heiman DI, Cao S, Maruvka YE, Lei JT, Huang C, Kothadia RB, Colaprico A, Birger C, Wang J, Dou Y, Wen B, Shi Z, Liao Y, Wiznerowicz M, Wyczalkowski MA, Chen XS, Kennedy JJ, Paulovich AG, Thiagarajan M, Kinsinger CR, Hiltke T, Boja ES, Mesri M, Robles AI, Rodriguez H, Westbrook TF, Ding L, Getz G, Clauser KR, Fenyo D, Ruggles KV, Zhang B, Mani DR, Carr SA, Ellis MJ, Gillette MA
    Clinical Proteomic Tumor Analysis Consortium (Contributors include: Li S)

    Cell 2020 Nov 25;183(5):1436-1456
  • Optimal Co-Clinical Radiomics: Sensitivity of Radiomic Features to Tumour Volume, Image Noise and Resolution in Co-Clinical T1-Weighted and T2-Weighted Magnetic Resonance Imaging
    Roy S, Whitehead TD, Quirk JD, Salter A, Ademuyiwa FO, Li S, An H, Shoghi KI
    EBioMedicine 2020 Sep;59:102963
  • Preclinical PERCIST and 25% of SUVmax Threshold: Precision Imaging of Response to Therapy in Co-Clinical (18)F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts
    Savaikar MA, Whitehead T, Roy S, Strong L, Fettig N, Prmeau T, Luo J, Li S, Wahl RL, Shoghi KI
    J Nucl Med 2020 Jun;61(6):842-849
  • Selective Imaging of Solid Tumours Via the Calcium-Dependent High-Affinity Binding of a Cyclic Octapeptide to Phosphorylated Annexin A2
    Shen D, Xu B, Liang K, Tang R, Sudlow GP, Egbulefu C, Guo K, Som A, Gilson R, Maji D, Mondal S, Habimana-Griffin L, Akers WJ, Li S, Liu Y, Bloch S, Kurkure S, Nussinov Z, Seidel A, Tsen SD, Achilefu S
    Nat Biomed Eng 2020 Mar;4(3):298-313
  • Test-Retest Performance of a 1-Hour Multiparametric MR Image Acquisition Pipeline With Orthotopic Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts
    Ge X, Quirk JD, Engelbach JA, Bretthorst GL, Li S, Shoghi KI, Garbow JR, Ackerman JJH
    Tomography 2019 Sep;5(3):320-331
  • Folate Receptor Alpha-Targeted (89)Zr-M9346A Immuno-PET for Image-Guided Intervention With Mirvetuximab Soravtansine in Triple-Negative Breast Cancer
    Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y
    Mol Pharm 2019 Sep 3;16(9):3996-4006
  • Regulated Phosphosignaling Associated With Breast Cancer Subtypes and Druggability
    Huang KL, Wu Y, Primeau T, Wang YT, Gao Y, McMichael JF, Scott AD, Cao S, Wendl MC, Johnson KJ, Ruggles K, Held JM, Payne SH, Davies S, Dar A, Kinsinger CR, Mesri M, Rodriguez H, Ellis MJ, Townsend RR, Chen F, Fenyo D, Li S, Liu T, Carr SA, Ding L
    Mol Cell Proteomics 2019 Aug;18(8):1630-1650
  • Assessment of Copper Nanoclusters for Accurate in Vivo Tumor Imaging and Potential for Translation
    Heo GS, Zhao Y, Sultan D, Zhang X, Detering L, Luehmann HP, Zhang X, Li R, Choksi A, Sharp S, Levingston S, Primeau T, Reichert DE, Sun G, Razani B, Li S, Weilbaecher KN, Dehdashti F, Wooley KL, Liu Y
    ACS Appl Mater Interfaces 2019 Jun 5;11(22):19669-19678
  • PI3K Inhibition Enhances the Anti-Tumor Effect of Eribulin in Triple Negative Breast Cancer
    Rajput S, Guo Z, Li S, Ma CX
    Oncotarget 2019 Jun 4;10(38):3667-3680
  • Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
    Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM
    Mol Cancer Ther 2019 Feb;18(2):399-412
  • Proteomic Profiling Identifies Key Coactivators Utilized by Mutant ERalpha Proteins as Potential New Therapeutic Targets
    Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, Hamilton RA, Yu Y, Lonard DM, Wang J, Wang SP, Edwards DG, Lavere PF, Shao J, Yi P, Jain A, Jung SY, Malovannaya A, Li S, Shao J, Roeder RG, Ellis MJ, Qin J, Fuqua SAW, O'Malley BW, Foulds CE
    Oncogene 2018 Aug;37(33):4581-4598
  • Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
    Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ
    Cell Rep 2018 Aug 7;24(6):1434-1444e7
  • Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers
    Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyo D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX
    Cancer Res 2018 May 15;78(10):2732-2746
  • RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells
    Yang X, Pan Y, Qiu Z, Du Z, Zhang Y, Fa P, Gorityala S, Ma S, Li S, Chen C, Wang H, Xu Y, Yan C, Ruth K, Ma Z, Zhang J
    Clin Cancer Res 2018 Apr 1;24(7):1629-1643
  • Identifying Biomarkers of Breast Cancer Micrometastatic Disease in Bone Marrow Using a Patient-Derived Xenograft Mouse Model
    Pillai SG, Li S, Siddappa CM, Ellis MJ, Watson MA, Aft R
    Breast Cancer Res 2018 Jan 2;20(1):2
  • Preclinical PET Imaging of Glycoprotein Non-Metastatic Melanoma B in Triple Negative Breast Cancer: Feasibility of an Antibody-Based Companion Diagnostic Agent
    Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, Ma CX, Lapi SE
    Oncotarget 2017 Nov 1;8(61):104303-104314
  • Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues
    Zhou JY, Chen L, Zhang B, Tian Y, Liu T, Thomas SN, Chen L, Schnaubelt M, Boja E, Hiltke T, Kinsinger CR, Rodriguez H, Davies SR, Li S, Snider JE, Erdmann-Gilmore P, Tabb DL, Townsend RR, Ellis MJ, Rodland KD, Smith RD, Carr SA, Zhang Z, Chan DW, Zhang H
    J Proteome Res 2017 Dec 1;16(12):4523-4530
  • Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
    Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ
    Cancer Discov 2017 Oct;7(10):1168-1183
  • Breast Tumors Educate the Proteome of Stromal Tissue in an Individualized but Coordinated Manner
    Wang X, Mooradian AD, Erdmann-Gilmore P, Zhang Q, Viner R, Davies SR, Huang KL, Bomgarden R, Van Tine BA, Shao J, Ding L, Li S, Ellis MJ, Rogers JC, Townsend RR, Fenyo D, Held JM
    Sci Signal 2017 Aug 8;10(491)
  • Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity
    Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, Miller CA, Ellis MJ, Mardis ER, Hansen T, Fleming TP, Goedegebuure SP, Gillanders WE
    Cancer Immunol Res 2017 Jul;5(7):516-523
  • Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
    Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S
    Cancer Res 2017 May 1;77(9):2476-2487
  • Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts
    Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyo D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L
    Nat Commun 2017 Mar 28;8:14864
  • Patient-Derived Xenograft (PDX) Models in Basic and Translational Breast Cancer Research
    Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT
    Cancer Metastasis Rev 2016 Dec;35(4):547-573
  • Inhibition of Cyclin Dependent Kinase 9 by Dinaciclib Suppresses Cyclin B1 Expression and Tumor Growth in Triple Negative Breast Cancer
    Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX
    Oncotarget 2016 Aug 30;7(35):56864-56875
  • Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer
    Lu J, McEachern D, Li S, Ellis MJ, Wang S
    Mol Cancer Ther 2016 Dec;15(12):2887-2893
  • Proteogenomics Connects Somatic Mutations to Signalling in Breast Cancer
    Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyo D, Ellis MJ, Carr SA
    NCI CPTAC (Contributors include: Li S)

    Nature 2016 May 25;534(7605):55-62
  • Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts
    Tabb DL, Wang X, Carr SA, Clauser KR, Mertins P, Chambers MC, Holman JD, Wang J, Zhang B, Zimmerman LJ, Chen X, Gunawardena HP, Davies SR, Ellis MJ, Li S, Townsend RR, Boja ES, Ketchum KA, Kinsinger CR, Mesri M, Rodriguez H, Liu T, Kim S, McDermott JE, Payne SH, Petyuk VA, Rodland KD, Smith RD, Yang F, Chan DW, Zhang B, Zhang H, Zhang Z, Zhou JY, Liebler DC
    J Proteome Res 2016 Mar 4;15(3):691-706
  • An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer
    Ruggles KV, Tang Z, Wang X, Grover H, Askenazi M, Teubl J, Cao S, McLellan MD, Clauser KR, Tabb DL, Mertins P, Slebos R, Erdmann-Gilmore P, Li S, Gunawardena HP, Xie L, Liu T, Zhou JY, Sun S, Hoadley KA, Perou CM, Chen X, Davies SR, Maher CA, Kinsinger CR, Rodland KD, Zhang H, Zhang Z, Ding L, Townsend RR, Rodriguez H, Chan D, Smith RD, Liebler DC, Carr SA, Payne S, Ellis MJ, Fenyo D
    Mol Cell Proteomics 2016 Mar;15(3):1060-71
  • QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues
    Gunawardena HP, O'Brien J, Wrobel JA, Xie L, Davies SR, Li S, Ellis MJ, Qaqish BF, Chen X
    Mol Cell Proteomics 2016 Feb;15(2):740-51
  • Integrated Bottom-Up and Top-Down Proteomics of Patient-Derived Breast Tumor Xenografts
    Ntai I, LeDuc RD, Fellers RT, Erdmann-Gilmore P, Davies SR, Rumsey J, Early BP, Thomas PM, Li S, Compton PD, Ellis MJ, Ruggles KV, Fenyo D, Boja ES, Rodriguez H, Townsend RR, Kelleher NL
    Mol Cell Proteomics 2016 Jan;15(1):45-56
  • Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
    Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S
    Clin Cancer Res 2015 Nov 15;21(22):5121-30
  • Comprehensive Quantitative Analysis of Ovarian and Breast Cancer Tumor Peptidomes
    Xu Z, Wu C, Xie F, Slysz GW, Tolic N, Monroe ME, Petyuk VA, Payne SH, Fujimoto GM, Moore RJ, Fillmore TL, Schepmoes AA, Levine DA, Townsend RR, Davies SR, Li S, Ellis M, Boja E, Rivers R, Rodriguez H, Rodland KD, Liu T, Smith RD
    J Proteome Res 2015 Jan 2;14(1):422-33
  • Targeting an IKBKE Cytokine Network Impairs Triple-Negative Breast Cancer Growth
    Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, Herndon J, Cohoon TJ, Fleming T, Tamayo P, Mesirov JP, Ogino S, Wong KK, Ellis MJ, Hahn WC, Barbie DA, Gillanders WE
    J Clin Invest 2014 Dec 1;124(12):5411-5423
  • Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels
    Mertins P, Yang F, Liu T, Mani DR, Petyuk VA, Gillette MA, Clauser KR, Qiao JW, Gritsenko MA, Moore RJ, Levine DA, Townsend R, Erdmann-Gilmore P, Snider JE, Davies SR, Ruggles KV, Fenyo D, Kitchens RT, Li S, Olvera N, Dao F, Rodriguez H, Chan DW, Liebler D, White F, Rodland KD, Mills GB, Smith RD, Paulovich AG, Ellis M, Carr SA
    Mol Cell Proteomics 2014 Jul;13(7):1690-704
  • Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
    Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, Deschryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ
    Cell Rep 2013 Sep 26;4(6):1116-30
  • Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-Like Breast Cancer in Patient-Derived Xenograft Models
    Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX
    Mol Cancer Ther 2013 Aug;12(8):1665-75
  • Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ
    Cancer Discov 2013 Feb;3(2):224-37
  • Targeting Chk1 in p53-Deficient Triple-Negative Breast Cancer Is Therapeutically Beneficial in Human-In-Mouse Tumor Models
    Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H
    J Clin Invest 2012 Apr 2;122(4):1541-52
  • Targeting the Akt/mTOR Pathway in Brca1-Deficient Cancers
    Xiang T, Jia Y, Sherris D, Li S, Wang H, Lu D, Yang Q
    Oncogene 2012 Jun 7;31(23):2876-87
  • Genome Remodelling in a Basal-Like Breast Cancer Metastasis and Xenograft
    Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin L, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF, Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS, Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du F, Hawkins AE, O'Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson DM Jr, Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson M, Ley TJ, Wilson RK, Mardis ER
    Nature 2010 Apr 15;464(7291):999-1005
  • WIF1, a Wnt Pathway Inhibitor, Regulates SKP2 and c-MYC Expression Leading to G1 Arrest and Growth Inhibition of Human Invasive Urinary Bladder Cancer Cells
    Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, Mercola D, Hoang BH, Zi X
    Mol Cancer Ther 2009 Feb;8(2):458-68
  • Angiotensin II and EGF Receptor Cross-Talk in Chronic Kidney Diseases: A New Therapeutic Approach
    Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F
    Nat Med 2005 Aug;11(8):867-74